Idebenone Therapy for Viral ARDS Lung Function Preservation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for Acute Respiratory Distress Syndrome (ARDS) associated with viral infections, particularly those caused by SARS-CoV-2, lack specific pharmacotherapies, leading to high mortality and long-term functional and psychological sequelae, with a need for improved management strategies to reduce respiratory complications and preserve lung function.

Innovation Solution

Administering idebenone, a synthetic compound similar to coenzyme Q10, in therapeutically effective doses to patients with viral infections, particularly COVID-19, to reduce respiratory function loss, bronchopulmonary complications, and the need for systemic antibiotics, potentially combined with other therapeutic agents like remdesivir or tocilizumab.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If lung-protective ventilation strategy is implemented, then patient survival is improved, but no specific pharmacotherapies are available leading to high mortality

Engineering Contradiction:
Improvepatient survivalVSAvoidmortality rate
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

Idebenone acts as a mediator substance that protects lung tissue from viral-induced damage. The compound functions as an intermediary agent between the virus and lung cells, reducing the harmful effects of viral infection through its antioxidant and anti-inflammatory properties, thereby lowering mortality without interfering with ventilation strategies

Inventive Principle:
Principle #24Intermediary (Mediator)

Solution Approach 2:

The invention changes the biochemical parameters of lung tissue by introducing idebenone, which alters the redox state and reduces oxidative stress. This parameter change in the biological system provides pharmacological protection that complements the mechanical lung-protective ventilation strategy

Inventive Principle:
Principle #35Parameter changes

2Reliability

If mechanical ventilation is used for ARDS patients, then respiratory failure is supported, but long-term functional and psychological sequelae occur

Engineering Contradiction:
Improverespiratory supportVSAvoidlong-term sequelae
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

Idebenone is administered early in the course of viral infection to prevent the development of severe ARDS and the need for prolonged mechanical ventilation. By acting preliminarily to protect lung tissue, the compound reduces the duration and intensity of ventilation required, thereby minimizing long-term functional and psychological sequelae

Inventive Principle:
Principle #10Preliminary action

Solution Approach 2:

The invention converts the harmful oxidative stress and inflammation caused by viral infection into a beneficial protective response by administering idebenone. The compound transforms the pathological process into a controlled protective mechanism that reduces tissue damage and accelerates recovery, decreasing the need for prolonged mechanical support

Inventive Principle:
Principle #22Blessing in disguise (Convert harm into benefit)

3Reliability

If specific pharmacotherapies are developed for ARDS, then mortality is reduced, but current treatments lack specificity leading to high mortality rates

Engineering Contradiction:
Improvemortality reductionVSAvoidpharmacotherapy specificity
Core Design Contradiction:
ReliabilityVSAdaptability or versatility

Solution Approach 1:

Idebenone provides universal pharmacological protection that can be applied to ARDS caused by various viruses including SARS-CoV-2. The compound's mechanism of action targets fundamental pathological processes (oxidative stress, inflammation) that are common across different viral infections, providing adaptable pharmacotherapy that reduces mortality regardless of the specific virus involved

Inventive Principle:
Principle #6Universality (Multi-functionality)

Data Source

PatentUS12514830B2Idebenone for the treatment of Acute Respiratory Distress Syndrome (ARDS) in patients diagnosed with a coronavirus infection
Publication Date: 2026.01.06 BEMIDO SA

AI summary

The present invention relates to idebenone for treating Acute Respiratory Distress Syndrome (ARDS) associated with a viral infection, particularly a coronavirus infection, such as Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).